BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Jair Bar, Nir Peled et al.|Journal of Thoracic Oncology|2018Cited by 220
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastasesElizabeth Dudnik, Nir Peled, Shlomit Yust‐Katz et al.|Lung Cancer|2016Cited by 136
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung CancersAlexander Drilon, Kristoffer Staal Rohrberg, Todd M. Bauer et al.|Journal of Thoracic Oncology|2019Cited by 81
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg et al.|OncoImmunology|2021Cited by 70